title: Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone.
abstract: Intermittent treatment with parathyroid hormone (PTH) increases bone mass in experimental animals and humans. In vitro studies have suggested that the anabolic effect of PTH may be mediated by local growth factors. However, the relevance of these findings to in vivo situations remains unclear. In this study, we examined a time course of daily s.c. injections of hPTH (1-34) on the skeletal concentration of insulin-like growth factor (IGF)-I, IGF-II, and transforming growth factor beta (TGF-beta) in the proximal tail vertebrae of male rats. PTH caused a time and dose-dependent increase in the bone mineral density of the lumbar spine. This anabolic effect on bone mass was accompanied by progressive increases in bone matrix-associated IGF-I and TGF-beta 1. Increases in IGF-I and TGF-beta 1 became apparent after four and eight weeks of PTH treatment respectively and persisted through week 12. PTH had no effect on circulating IGF-I, suggesting that the increase of bone matrix IGF-I was due to the local effect of PTH on bone tissue directly rather than to an increase of circulating IGF-I. These data are consistent with the hypothesis that IGF-I and TGF-beta 1 may play a role as local mediators of the anabolic effects of PTH on bone metabolism.
authors.affiliation: University of Heidelberg, Department of Internal Medicine, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Pfeilschifter
authors.forename: F
authors.initials: F
authors.lastname: Laukhuf
authors.forename: B
authors.initials: B
authors.lastname: Müller-Beckmann
authors.forename: W F
authors.initials: WF
authors.lastname: Blum
authors.forename: T
authors.initials: T
authors.lastname: Pfister
authors.forename: R
authors.initials: R
authors.lastname: Ziegler
mesh_terms: D000367:Age Factors; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D007279:Injections, Subcutaneous; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis* / Q000235:genetics; D007335:Insulin-Like Growth Factor II / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013268:Stimulation, Chemical; D019379:Teriparatide; D016212:Transforming Growth Factor beta / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D010281:Parathyroid Hormone; D010446:Peptide Fragments; D016212:Transforming Growth Factor beta; D019379:Teriparatide; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II